Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 0.86 |
| ▸ | BMX | P51813 | 2/20 | 0.86 |
| ▸ | JAK3 | P52333 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410852 | 1.00 | BTK (1.00) | BTKEGFRBMXJAK3 | |
| SCHEMBL20716663 | 0.95 | BTK (1.00) | BTKEGFRBMXJAK3 | |
| SCHEMBL20716456 | 0.94 | BTK (1.00) | BTKEGFRBMXJAK3 | |
| SCHEMBL29410891 | 0.94 | BTK (1.00) | BTKEGFRBMXJAK3 | |
| SCHEMBL20716479 | 0.93 | BTK (1.00) | BTKEGFRBMXJAK3 | |
| SCHEMBL29410873 | 0.93 | BTK (1.00) | BTKEGFRBMXJAK3 | |
| SCHEMBL19230221 | 0.93 | BTK (1.00) | BTKEGFRBMXJAK3 | |
| SCHEMBL31105580 | 0.93 | BTK (1.00) | BTKEGFRBMXJAK3 | |
| SCHEMBL20716646 | 0.93 | BTK (1.00) | BTKEGFRBMXJAK3 | |
| SCHEMBL20716914 | 0.93 | BTK (1.00) | BTKEGFRBMXJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107033069-B | Novel irreversible Bruton's tyrosine kinase inhibitor | 中国科学院合肥物质科学研究院 | 2022-03-04 | — | — | CN | disclosed |
| US-10669238-B2 | Irreversible bruton's tyrosine kinase inhibitor | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190040013-A1 | NOVEL IRREVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669238-B2 | Irreversible bruton's tyrosine kinase inhibitor | BTK, ABL1, SYK | BTK 1/4885EGFR 441/4885BMX 10/4885 |
| US-20190040013-A1 | NOVEL IRREVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR | BTK, ABL1, SYK | BTK 1/4885EGFR 591/4885BMX 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.